Please login to the form below

Not currently logged in
Email:
Password:

Eric Cornut appointed EFPIA interim director general

Steps into the role as Richard Bergström leaves the association

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Eric Cornut as its interim director general, following the resignation of Richard Bergström from the post.

Currently an independent consultant based in Basel, Switzerland, Cornut brings over 25 years of pharmaceutical management experience to the role, including five years as chairman of EFPIA's executive committee.

He most recently served as chief ethics, compliance and policy officer at Novartis, taking up the position in 2014 after a four-year stint as chairman of the board for Novartis Japan.

Having first joined Novartis in 1997 as a general manager in The Netherlands, Cornut has held a number of increasingly senior managerial roles at the Swiss pharma firm, including president of Novartis France, head of Europe and chief commercial officer.

Joe Jiminez, president of EFPIA, said: “Eric brings a wealth of valuable experience, having worked in the pharmaceutical industry for more than 25 years with responsibility for both commercial and policy work.

“I am very pleased that Eric accepted to lead EFPIA ad interim.”

5th January 2017

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...

Infographics